UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL											
OMB Number: 3235-0287											
Estimated average be	urden										
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	(Fi H PARK 2/4 X 39098	rst) (4 GIVAT-RAM 3 9	Middle) 21390 Zip)	on Dori	3. Dat 09/1:	ORAMED PHARMACEUTICALS INC. [ORMP] 3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)									(Check all applicable) Director 10% Owner X Officer (give title below) CFO, Treasurer and Secretary 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Cially Owned					
1. Title of	Security (Ins		ction ay/Year)	2A. Deemed Execution Date,				3. 4. Securities Acquired (Transaction Disposed Of (D) (Instr. Code (Instr. and 5)				5. Amou Securitie Beneficia Owned Followin Reported Transact (Instr. 3	s ally g I ion(s)	Form (D) or Indire (Instr		. Nature of Indirect Seneficial Ownership Instr. 4)				
			Tabl								sed of, or			vned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/		Code (In	4. 5. Number of Derivative Securities				6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) Compared to the co				8. Price of Derivative Security (Instr. 5)	derivative Securitie Ity Beneficia		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code			(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)					
Stock Option (right to buy)	\$3.55	06/17/2019			D ⁽¹⁾	D ⁽¹⁾		33,146	(1)		06/17/2029	Common Stock	33,146	\$0	0		D			
Stock Option (right to buy)	\$3.55	09/12/2019			A ⁽¹⁾		33,146		(1)		09/12/2029	Common Stock	33,146	\$0	33,14	6	D			

Explanation of Responses:

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on June 17, 2019 and provides for vesting in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022.

09/12/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** Signature of Reporting Person

Date

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL											
OMB Number: 3235-0287											
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	Name and Address of Reporting Person* KIDRON NADAV								er or Tradi RMACI				ationship of all applical Director	ole)	ng Per	10% O	wner	
(Last) 142 W. 57TF	(First)	(Middle)				e of Earlie 2/2019	est Transa	action (Mo	nth/[Day/Yea	X	X Officer (give title Other (specify below) below) President and CEO					
(Street) NEW YORK (City)	NY (State		10019 Zip)		4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X	ridual or Joint/Group Filing (Check Applicab Form filed by One Reporting Person Form filed by More than One Reporting Person			on	
		Tab	le I - N	on-De	erivati	ve S	ecuriti	es Acq	uired, D)isp	osed	of, or Bei	eficially	Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) Transactio Code (Inst					tr. and 5)					Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Table						,		,	or Benefic e securitie	•	ed				
1. Title of 2. 3. Transaction 3A. Deemed 4. T						action istr.	5. Number Derivative Acquired Disposed (Instr. 3, 4	Securities (A) or of (D)	6. Date Exercisable and 7. Title and Amount				lerlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned		10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security				Code	v	(A)	(D)	Date Exercisable		iration e	Title	Amount or Number of Shares		Following Reported Transacti (Instr. 4)	d ion(s)	(I) (Instr. 4)	
Stock Option (right to buy)	\$3.16	02/26/2019			D ⁽¹⁾			196,500	(1)	02/	26/2029	Common Stock	196,500	\$0	0		D	
Stock Option (right to buy)	\$3.16	09/12/2019			A ⁽¹⁾		196,500		(1)	09/	12/2029	Common Stock	196,500	\$0	196,5	00	D	

Explanation of Responses:

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

<u>/s/ Nadav Kidron</u> <u>09/12/2019</u>

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL											
OMB Number: 3235-0287											
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A Kidron Mi		Reporting Persor	*		<u>C</u>	DR/	AMED		er or Tradi	_	•	LS	INC. [tionship of all applicat Director		g Per	son(s) to I:	
(Last) 2 ELZA STR	(First)) (Middle)		3	ORMP] 3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019									Officer (give title Other (spec below) below) Chief Scientific Officer			specify	
(Street) JERUSALEN (City)	M L3) e) (4	4. If Amendment, Date of Original Filed (Month/Day/Year)									ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution Date, if any (Month/Day/Year) (Month/Day/Year)						d (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Table						ired, Dis options,					illy Owne	d			'	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution any (Month/Da	Date, if	4. Trans Code (Ir 8)		5. Number Derivative Acquired Disposed (Instr. 3, 4	Securities (A) or of (D)	6. Date Exercisable and F. Title and Amour Securities Underly Derivative Security and 4)					lying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned		10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security		Code	v	(A)	(D)	Date Exercisable		oiration te	Title		Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)		(I) (Instr. 4)			
Stock Option (right to buy)	\$3.16	02/26/2019			D ⁽¹⁾	104,000		(1)	02/	26/2029		mmon tock	104,000	\$0	0		D		
Stock Option (right to buy)	\$3.16	09/12/2019			A ⁽¹⁾	104,000			(1)	(1) 09/12/2029		Common Stock 1		104,000	\$0	\$0 104,000		D	

Explanation of Responses:

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

/s/ Miriam Kidron

09/12/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL												
OMB Number:	OMB Number: 3235-0287											
Estimated average b	urden											
hours per response:	0.5											

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	(Fi	E	Middle)		ORM ORM 3. Dat 09/12	Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP] Description of the Indian Symbol ORAMED PHARMACEUTICALS INC. [ORMP] One of Earliest Transaction (Month/Day/Year) 09/12/2019 If Amendment, Date of Original Filed (Month/Day/Year)									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below) Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(St	tate) (Zip)										Person								
		Tab	le I - N	on-Deriv	ative S	Sec	urities	s Acq	uired,	Disp	osed of,	or Ben	eficiall	y Owned							
1. Title of	Security (Ins	2. Transa Date (Month/D		Execution Date,				3. 4. Securiti Disposed Code (Instr. 8)				5. Amour Securitie Beneficia Owned Followin	es ally	Form: Direct (D) or Indirect (I)		'. Nature of Indirect Beneficial Ownership Instr. 4)					
							Code	v	Amount	(D)		Reported Transaction(s) (Instr. 3 and 4)		, ,							
			Tabl								sed of, or nvertible			vned							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed on Date, Day/Year)	4. Transact Code (In 8)		5. Num Derivat Securit Acquir or Disp of (D) (3, 4 an	tive ties ed (A) oosed Instr.	6. Date Expirati (Month)	ion D		7. Title a Amount Securitie Underlyi Derivativ Security and 4)	of s ng e	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Followin Reported	e Ownersh Form: Direct (D or Indire g (I) (Instr.		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		Transact (Instr. 4)	ion(s)					
Stock Option (right to buy)	\$4.17	04/10/2019			D ⁽¹⁾			10,000	12/31/2	019	04/10/2029	Common Stock	10,000	\$0	0		D				
Stock Option (right to buy)	\$4.17	09/12/2019			A ⁽¹⁾		10,000		12/31/2	019	09/12/2029	Common Stock	10,000	\$0	10,00	00	D				

Explanation of Responses:

1. The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option.

<u>/s/ Kevin Rakin</u> <u>09/12/2019</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) 9 ALFAS	· Joshua (Fi	of Reporting Person	* Middle)		ORA ORM 3. Dat 09/12	Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP] ORMP] 3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)									cable) or (give title) hf. Op. &	Bus.	g Person(s) to Issuer 10% Owner Other (specification) Bus. Officer Divining (Check Application)	
(Street) JERUSA			02302												•		orting Person	
(City)	(S		Zip)															
1. Title of	Security (Ins	rative S	Execution Date,				4. Securities Disposed Of and 5)		ities Acqu d Of (D) (Ir	ired (A) or	5. Amo Securit Benefic Owned	. Amount of Securities Beneficially Dwned Following		n: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership			
								Code	′	Amount	ount (A) or (D)		Transa (Instr. 3	ction(s)				
			Tabl						uired, Dis , options,					wned				
1. Title of Derivative Security (Instr. 3)	tle of 2. 3. Transaction 3A. Deemed Execution Date if any					4. 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and F. Title a Expiration Date (Month/Day/Year) Securitie Underlyi Derivativ (Instr. 3 a				of s ng e Security	8. Price of Derivative Security (Instr. 5)	of derivative Derivative Securities Security Beneficia		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock option (right to buy)	\$3.69	09/12/2019			A		100,000		(1)	09)/12/2029	Common Stock	100,000	\$0	100,00	00	D	

Explanation of Responses:

1. The Stock Options will vest in 16 equal installments of 6,250 on the first day of every three month period beginning November 1, 2019.

<u>/s/ Joshua Hexter</u> <u>09/12/2019</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).